R-Cin 100mg Suspension

Interaction

Drug :- aminophylline, oxtriphylline, theophylline: Increased metabolism and clearance of these theophylline preparations.

anesthetics hydrocarbon inhalation, except isoflurane, hepatotoxic drugs, isoniazid: Increased risk of hepatotoxicity.

beta blockers, chloramphenicol, clofibrate, corticosteroids, cyclosporine, dapsone, digitalis glycosides, disopyramide, hexobarbital, itraconazole, ketoconazole, mexiletine, oral anticoagulants, oral antidiabetic drugs, phenytoin, propafenone, quinidine, tocainide, verapamil oral: Increased metabolism, resulting in lower blood levels of these drug.

bone marrow depressants: Increased leukopenic or thrombocytopenic effects.

clofazimine: Reduced absorption of rifampin, delaying its peak concentration and increasing its half-life.

diazepam: Enhanced diazepam elimination, resulting in decreased drug effectiveness.

estramustine, estrogens, oral contraceptives: Decreased estrogenic effects.

methadone: Possibly impaired absorption of methadone, leading to withdrawal symptoms.

probenecid: Increased blood level or prolonged duration of rifampin, increasing risk of toxicity.

nonnucleoside reverse transcriptase inhibitors, protease inhibitors indinavir, nelfinavir, ritonavir, saquinavir: Accelerated metabolism of these drugs by patients with HIV, resulting in subtherapeutic levels,delayed metabolism of rifampin, increasing risk of toxicity.

trimethoprim: Increased elimination and shortened elimination half-life of trimethoprim.

vitamin D: Increased metabolism and decreased efficacy of vitamin D, leading to decreased serum calcium and phosphate levels and increased parathyroid hormone levels.

Activity :- alcohol use: Increased risk of hepatotoxicity.